Takeda Pharmaceutical Co ADRTAK
Price$17.86Intrinsic value$6.8961% below price

Valuation

How Intrinsic Value compares with model outputs

Intrinsic Value $6.89median of 6 methods · middle span $0-$20based on filings through 31 Mar 2025
Market Price $17.86Price as of 1 Oct 2026
Margin of Safety -61.4%as of 1 Oct 2026

Valuation methods vs. Market Price

Company vs. peer median Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions

ParameterValue
Years 1–5: analyst growth pathFive-year total matches analyst consensus exactly. Year 1: 60.0% (near-term consensus, capped) · years 2–5: 17.3%/yr (balance of the path).24.8% per year
Years 6–10: glide to demonstrated growth
Per-year rates
Yr 614.4%Yr 711.6%Yr 88.7%Yr 95.9%Yr 103.0%
17.3% → 3.0%
Years 11–20: glide to long-run rate
Per-year rates
Yr 113.0%Yr 123.0%Yr 133.0%Yr 143.0%Yr 153.0%Yr 163.0%Yr 173.0%Yr 183.0%Yr 193.0%Yr 203.0%
3.0% → 3.0%
Beyond year 20: terminal growthPerpetual long-run rate3.0%
Historical EPS growth (multi-year median)median of 3 windows (5/6/7y)-11.5%
Discount rate (cost of equity) 6.7%
Volatility vs market (adjusted beta)0.40

Valuation Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Assumptions Sandbox Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up

Compare with peers

Search any company to compare valuation, profitability, returns, growth, and financial strength side by side.

Compare the target company plus 1 peer. Sign in / Sign up to compare a maximum of 3 peers.

Best in rowHigher is betterLower is better—Data not available
TargetTakeda Pharmaceutical Co ADRTAKHealth Care
Valuation
P/E—
P/S0.0×
P/B0.0×
EV / Revenue1.1×
EV / EBITDA—
Profitability
Gross margin—
Operating margin7.5%
Net margin2.4%
FCF margin18.7%
Returns
ROE1.6%
ROA0.8%
ROIC—
Growth
Revenue growth (YoY)8.4%
5-yr fwd EPS growth24.8%
Financial strength
Debt / Equity—
Current ratio1.01×
Altman Z-Score—
Interest coverage—
Dividend yield1.8%

Best value in each row is highlighted. Figures are periodic snapshots from the same filings used across each dossier; a dash means the figure is not available.

AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.